Synthesis, structure, and structure-activity relationships of divalent thrombin inhibitors containing an α-keto-amide transition-state mimetic

Protein Science

Volumn 5, Issue 3, 1996, Pages 422-433

  Krishnan, Raman ^a   Tulinsky, A ^a   Vlasuk, George P ^b   Pearson, Daniel ^b   Vallar, Pureza ^b   Bergum, Peter ^b   Brunck, Terence K ^b   Ripka, William C ^b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b Dendreon   (United States)

Author keywords

divalent inhibitors; transition state; X ray crystallographic structure; keto amide

Indexed keywords

DIVALENT CATION; HIRUDIN; THROMBIN INHIBITOR;

AMINO TERMINAL SEQUENCE; ARTICLE; ENZYME ACTIVATION; ENZYME ACTIVE SITE; HEMOSTASIS; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; STRUCTURE ACTIVITY RELATION; THROMBOCYTE ACTIVATION; X RAY CRYSTALLOGRAPHY;

EID: 0029879577     PISSN: 09618368     EISSN: None     Source Type: Journal    
DOI: 10.1002/pro.5560050303     Document Type: Article

References (54)

1. Banner DW, Hadvary P. 1991. Crystallographic analysis at 3.0 Å resolution of the binding to human thrombin of four active site-directed inhibitors. J Biol Chem 266:20085-20090.
2. Betz A, Hofsteenge J, Stone SR. 1991. Role of interactions involving C-terminal nonpolar residues of hirudin in the formation of the thrombin-hirudin complex. Biochemistry 30:9848-9853.
3. Bode W, Mayr I, Baumann U, Huber R, Stone SR, Hofsteenge J. 1989. The refined 1.9 Å crystal structure of human α-thrombin: Interaction with D-Phe-Pro-Arg chloromethyl ketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J 8:3467-3475.
4. Bode W, Turk D, Karshikov A. 1992. The refined 1.9 Å X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human α-thrombin. Structure analysis, overall structure, electrostatic properties, detailed active-site geometry, structure-function relationships. Protein Sci 1: 426-471.
5. Cha S. 1975. Tight-binding inhibitors. I. Kinetic behavior. Biochem Pharmacol 24:2177-2185.
6. Chirgadze NY, Clawson DK, Gesellchen PD, Hermann RB, Kaiser RE Jr., Olkowski JL, Sall DJ, Schevitz RW, Smith GF, Shuman RT, Wery JP, Jones ND. 1992. The X-ray structure at 2.2 Å resolution of a ternary complex containing human α-thrombin, a hirudin peptide (54-65) and an active site inhibitor. Pittsburgh, Pennsylvania: ACA Annual Meeting, August 9-14. Abstract PB33.
7. Coughlin SR. 1994. Thrombin receptor function and cardiovascular disease. Trends Cardiovasc Med 4:77-83.
8. DiMaio J, Gibbs B, Lefebre J, Konishi Y, Munn D, Yue SY. 1992. Synthesis of a homogeneous series of ketomethylene arginyl pseudopeptides and application to low molecular weight hirudin-like thrombin inhibitors. J Med Chem 35:3331-3341.
9. DiMaio J, Gibbs B, Munn D, Lefebre J, Ni F, Konishi Y. 1990. Bifunctional thrombin inhibitors based on the sequence of hirudin 45-65. J Biol Chem 265:21698-21703.
10. DiMaio J, Gibbs B, Munn D, Lefebre J, Ni F, Konishi Y. 1991. A new class of potent thrombin inhibitors that incorporates a scissile pseudopeptide bond. FEBS Lett 282:47-52.
11. Erhlich HJ, Grinnell BW, Jaskunas SR, Esmon CT, Yan SB, Bang NV. 1990. Recombinant human protein C derivatives: Altered response to calcium resulting in enhanced activation by thrombin. EMBO J 9:2367-2373.
12. Esmon CT. 1989. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 204:4743-4746.
13. Fenton JW. 1981. Thrombin specificity. Ann NY Acad Sci 370:468-495.
14. Fenton JW. 1986. Thrombin. Ann NY Acad Sci 455:5-15.
15. Fusetani N, Matsunaga S, Matsumoto H, Takebayashi Y. 1990. Cyclotheonamide: Potent thrombin inhibitors from a marine sponge Theonella sp. J Am Chem Soc 112:7053-7054.
16. Grutter MG, Priestle JP, Rahuel J, Grossenbacher H, Bode W, Hofsteenge J, Stone SR. 1990. Crystal structure of the thrombin-hirudin complex: A novel mode of serine protease inhibition. EMBO J 9:2361-2365.
17. Hagihara M, Schreiber SL. 1992. Reassignment of stereochemistry and total synthesis of the thrombin inhibitor cyclotheonamide B. J Am Chem Soc 114:6570-6571.
18. Hendrickson WA. 1985. Stereochemically restrained refinement of macromolecular structures. Methods Enzymol 115B:252-270.
19. Howard AJ, Gilliland GL, Finzel BC, Poulos TL, Ohlendorf DH, Salemme FR. 1987. The use of an imaging proportional counter in macromolecular crystallography. J Appl Crystallogr 20:383-387.
20. Ishii K, Gerszten R, Zheng YW, Welsh JB, Turck CW, Coughlin SR. 1995. Determinants of thrombin receptor cleavage. J Biol Chem 270:16435-16440.
21. Jones TA. 1982. A graphics model building and refinement system for macromolecules. J Appl Crystallogr 15:23-31.
22. Kline T, Hammond C, Bourdan P, Maraganore J. 1991. Hirulog peptides with scissile bond replacements resistant to thrombin cleavage. Biochem Biophys Res Commun 177:1049-1055.
23. Le Bonniec BF, Esmon CT. 1991. Glu 192 → Gln substitution in thrombin mimics the catalytic switch induced by thrombomodulin. Proc Natl Acad Sci USA 88:7371-7375.
24. Lee AY, Hagihara M, Karmacharya R, Albers MW, Schreiber SL, Clardy J. 1993. Atomic structure of the trypsin-cyclotheonamide complex: Lessons for the design of serine protease inhibitors. J Am Chem Soc 115: 12619-12620.
25. Lewis SD, Ng AS, Baldwin JJ, Fusetani N, Naylor AM, Shafer JA. 1993. Inhibition of thrombin and other trypsin-like serine proteinases by cyclotheonamide A. Thromb Res 70:173-190.
26. Mann KG. 1994. Prothrombin and thrombin. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 3rd ed. Philadelphia, Pennsylvania: J. B. Lippencott, Co. pp 184-199.
27. Maraganore JM. 1993. Thrombin, thrombin inhibitors, and the arterial thrombotic process. Thromb Haemostasis 70:208-211.
28. Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW. 1990. Design and characterization of hirulogs: A novel class of bivalent peptide inhibitors of thrombin. Biochemistry 29:7095-7101.
29. Markwardt F. 1989. Development of hirudin as an antithrombotic agent. Sem Thromb Haemost 15:269-282.
30. Martin PD, Robertson W, Turk D, Huber R, Bode W, Edwards BFP. 1992. The structure of residues 7-16 of the Aα-chain of human fibrinogen bound to bovine thrombin at 2.3 Å resolution. J Biol Chem 267:7911-7920.
31. Maryanoff BE, Qiu X, Padmanabhan KP, Tulinsky A, Almond HR Jr, Andrade-Gordon P, Greco MN, Kaufman JA, Nicolaou KC, Liu A, Brung PH, Fusetani N. 1993. Molecular basis for the inhibition of human-thrombin by the macrocyclic peptide cyclotheonamide A. Proc Natl Acad Sci USA 90:8048-8052.
32. Mathews H, Padmanabhan KP, Ganesh V, Tulinsky A, Ishii M, Chen J, Turck CW, Coughlin SR, Fenton JW II. 1994. Crystallographic structures of thrombin complexed with thrombin receptor peptides: Existence of expected and novel binding modes. Biochemistry 35:3266-3279.
33. Morrison JF. 1982. The slow, tight-binding inhibition of enzyme-catalyzed reactions. Trends Biochem Sci 7:102-105.
34. Powers JC, Harper JW. 1986. Inhibitors of serine proteinases. In: Barrett AJ, Salvesen G, eds. Proteinase inhibitors. The Netherlands: Elsevier Science Publishers B.V. (Biomedical Division). pp 55-152.
35. Priestle JP, Rahuel J, Rink H, Tones M, Grutter MG. 1993. Changes in interactions in complexes of hirudin derivatives and human-thrombin due to different crystal forms. Protein Sci 2:1630-1642.
36. Qiu X, Padmanabhan KP, Carperos VE, Tulinsky A, Kline T, Maraganore JM, Fenton JW II. 1992. Structure of the hirulog 3-thrombin complex and nature of the S' subsites of substrates and inhibitors. Biochemistry 31:11689-11697.
37. Qiu X, Yin M, Padmanabhan KP, Krstenansky JL, Tulinsky A. 1993. Structures of thrombin complexes with a designed and a natural exosite peptide inhibitor. J Biol Chem 268:20318-20326.
38. Rydel TJ, Ravichandran KG, Tulinsky A, Bode W, Huber R, Roitsch C, Fenion JW II. 1990. The structure of a complex of recombinant hirudin and human-thrombin. Science 249:277-280.
39. Rydel TJ, Tulinsky A, Bode W, Huber R. 1991. Refined structure of the hirudin-thrombin complex. J Mol Biol 221:583-601.
40. Sadler JE, Lentz SR, Sheehan JP, Tsiang M, Wu Q. 1993. Structure-function relationships of the thrombin-thrombomodulin interaction. Haemostasis 23:183-193.
41. Skrzypczak-Jankun E, Carperos VE, Ravichandran KG, Tulinsky A, Westbrook M, Maraganore JM. 1991. Structure of the hirugen and hirulog 1 complexes of thrombin. J Mol Biol 221:1379-1393.
42. Stenflo J, Fernlund P. 1982. Amino acid sequence of the heavy chain of protein C. J Biol Chem 257:12180-12190.
43. Stubbs MT, Oschkinat H, Mayr I, Huber R, Angliker H, Stone SR, Bode W. 1992. The interaction of thrombin with fibrinogen: A structural basis of its specificity. Eur J Biochem 206:187-193.
44. Szewczuk Z, Gibbs BF, Yue SY, Purisima E, Konishi Y. 1992. Conformationally restricted thrombin inhibitors resistant to proteolytic digestion. Biochemistry 37:9132-9140.
45. Szewczuk Z, Gibbs BF, Yue SY, Purisima E, Zdanov A, Cygler M, Konishi Y. 1993. Design of linker for trivalent thrombin inhibitors: Interaction of main chain of the linker with thrombin. Biochemistry 32:3396-3404.
46. Tulinsky A, Blevins RA. 1987. Structure of a tetrahedral transition state complex of an α-chymotrypsin dimer at 1.8 Å resolution. J Biol Chem 262: 7737-7742.
47. Tulinsky A, Qiu X. 1993. Active site and exosite binding of α-thrombin. Blood Coag Fibrinolysis 4:305-312.
48. Van Duyne GD, Standaert RF, Karplus PA, Schreiber SL, Clardy J. 1991. Atomic structure of FKBP-FK506, an immunophilin-immunosuppressant complex. Science 252:839-842.
49. Vijayalakshmi J, Padmanabhan KP, Mann KG, Tulinsky A. 1994. The isomorphous structures of prethrombin2, hirugen-and PPACK-thrombin: Changes accompanying activation and exosite binding. Protein Sci 3: 2254-2271.
50. Vu TKH, Hung DT, Wheaton VI, Coughlin SR. 1991a. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64:1057-1068.
51. Vu TKH, Wheaton VI, Hung DT, Charo I, Coughlin SR. 1991b. Domains specifying thrombin-receptor interaction. Nature 353:674-677.
52. Wilcox JN, Rodriguez J, Subramaman R, Ollerenshaw J, Zhong C, Hayzer DJ, Horaist C, Hanson SR, Lumsen A, Salam TA, Kelly AB, Harker LA, Runge M. 1994. Characterization of thrombin receptor expression during vascular lesion formation. Circ Res 75:1029-1038.
53. Williams JW, Morrison JF. 1979. The kinetics of reversible tight-binding inhibition. Methods Enzymol 63:437-467.
54. Zdanov A, Wu S, DiMaio J, Konishi Y, Li Y, Wu X, Edwards BFP, Martin PD, Cygler M. 1993. Crystal structure of the complex of human α-thrombin and nonhydrolyzable bifunctional inhibitors, hirutonin-2 and hirutonin-6 Proteins Struct Fund Genet 17:252-265.